Defunct Company
Total Trials
8
As Lead Sponsor
7
As Collaborator
1
Total Enrollment
536
NCT03267745
Effects of Amino Acid Formulation on Healthy Men Undergoing Unilateral Knee Immobilization
Phase: N/A
Role: Collaborator
Start: Aug 30, 2017
Completion: Aug 1, 2018
NCT04073368
Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Role: Lead Sponsor
Start: Dec 3, 2018
Completion: Sep 3, 2020
NCT04147936
Study of the Safety and Tolerability of AXA1665 in Subjects With Mild and Moderate Hepatic Insufficiency
Start: Mar 30, 2019
Completion: Jun 24, 2020
NCT04073407
Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD)
Start: Jul 27, 2019
Completion: Sep 1, 2020
NCT04134299
To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease
Start: Sep 25, 2019
Completion: Jan 11, 2021
NCT04880187
Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis
Phase: Phase 2
Start: May 7, 2021
Completion: Oct 31, 2023
NCT04816916
Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy
Start: Jun 29, 2021
Completion: Jun 30, 2022
NCT05152849
Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection
Start: Dec 15, 2021
Completion: Jun 29, 2022